Staff Members - Benha University
Potential Mechanisms Underlying the Renoprotective Effect of Empagliflozin, a Novel Selective Sodium Glucose Co-transporter (SGLT) 2 Inhibitor, against Diabetic Nephropathy in Streptozotocin Induced Diabetic Rats
• 2021
Publication Information
Authors
Mona A. Said and Hend A. Abdallah
Keywords
Not Available
Journal
Not Available
Publisher
Not Available
Volume
Not Available
Issue
Not Available
Pages
Not Available
publication.type
Local
Paper Link
Not Available
Supplementary Materials
Not Available
Abstract
Background: Diabetic nephropathy is a major microvascular complication of diabetes
and a primary cause of end-stage renal disease worldwide. This study was designed to
assess whether control of hyperglycemia with empagliflozin, a new sodium glucose cotransporter (SGLT) 2 inhibitor could improve the renal functions in streptozotocin
induced diabetic rats. Thirty two adult male albino rats were randomly assigned into four
equal groups. Group I; non diabetic control, Group II; non diabetic rats treated with
empagliflozin, group III; diabetic rats and group IV; diabetic rats treated with
empagliflozin. Diabetic rats treated with empagliflozin showed significant increase in
body weight and significant reduction in Kidney weight, blood glucose and glycated
haemoglobin (HbA1c) levels. Empagliflozin also produced significant decrease in blood
urea nitrogen (BUN), serum creatinine, urinary albumin excretion (UAE), tumor necrosis
factor alpha (TNF-α), interleukin 6 (IL-6) and transforming growth factor beta-1 (TGFβ1). It also attenuated Kidney tissue oxidative stress. Empagliflozin showed a
renoprotective effect in streptozotocin induced diabetic rats through its glucose lowering
effect and by reducing oxidative stress, inflammation, fibrosis and histopathological
alterations. SGLT-2 inhibitor seems to be a promising therapeutic strategy for managing
diabetes mellitus to slow the progression of diabetic nephropathy.
and a primary cause of end-stage renal disease worldwide. This study was designed to
assess whether control of hyperglycemia with empagliflozin, a new sodium glucose cotransporter (SGLT) 2 inhibitor could improve the renal functions in streptozotocin
induced diabetic rats. Thirty two adult male albino rats were randomly assigned into four
equal groups. Group I; non diabetic control, Group II; non diabetic rats treated with
empagliflozin, group III; diabetic rats and group IV; diabetic rats treated with
empagliflozin. Diabetic rats treated with empagliflozin showed significant increase in
body weight and significant reduction in Kidney weight, blood glucose and glycated
haemoglobin (HbA1c) levels. Empagliflozin also produced significant decrease in blood
urea nitrogen (BUN), serum creatinine, urinary albumin excretion (UAE), tumor necrosis
factor alpha (TNF-α), interleukin 6 (IL-6) and transforming growth factor beta-1 (TGFβ1). It also attenuated Kidney tissue oxidative stress. Empagliflozin showed a
renoprotective effect in streptozotocin induced diabetic rats through its glucose lowering
effect and by reducing oxidative stress, inflammation, fibrosis and histopathological
alterations. SGLT-2 inhibitor seems to be a promising therapeutic strategy for managing
diabetes mellitus to slow the progression of diabetic nephropathy.